Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

Jarrett J. Failing, Olivia A. Dudek, Julian A. Marin Acevedo, Razvan M. Chirila, Haidong M Dong, Svetomir Nenad Markovic, Roxana S Dronca

Research output: Contribution to journalReview article

1 Scopus citations


Hyperprogression and pseudoprogression are two atypical responses to immune checkpoint inhibitor therapy that affect therapeutic decisions and prognosis. Identification of predictive biomarkers for atypical responses either before or during treatment remains a huge unmet need in cancer immunotherapy. Many studies have looked at potential biomarkers, including clinical factors and laboratory findings (e.g., peripheral blood counts, circulating tumor DNA, cytokine levels). The results of these studies have been inconsistent, possibly due to small sample sizes, different tumor types and heterogeneity of the definition of these atypical responses.

Original languageEnglish (US)
Pages (from-to)2645-2656
Number of pages12
JournalFuture Oncology
Issue number22
StatePublished - Aug 1 2019



  • atypical response
  • biomarker
  • hyperprogression
  • immune checkpoint inhibitor
  • immunotherapy
  • pseudoprogression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this